TSTobias Schreiber

Tobias Schreiber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tobias Schreiber has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick Nagel

    Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Germany

    4 shared publications
  • Ulf Landmesser

    Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Germany

    4 shared publications
  • Gerhard Hindricks

    Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Johannes Lucas

    Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Martin Huemer

    Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Philipp Attanasio

    Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications

Latest Publications

  • Open Access

    Comparison of therapeutic strategies in patients presenting with left atrial thrombus despite oral anticoagulation

    by Tobias Schreiber, Patrick Nagel, Johannes Lucas, Anja Cretnik, Laura Isabel Adler, Verena Tscholl, Ulf Landmesser, Gerhard Hindricks, Anna Sannino, Andi Rroku, et al.

    Background: Left atrial appendage (LAA) thrombus formation is associated with elevated stroke risk and mortality. This study was designed to compare different therapeutic strategies in patients presenting with LAA thrombi despite adequate oral anticoagulation (OAC) therapy. Methods: In this retrospective single-center study, patients with atrial fibrillation (AF) and LAA thrombus despite adequate OAC for more than three weeks were identified. A follow-up transesophageal echo (TEE) was performed at least four weeks after the initial TEE. Thrombus resolution was assessed for each treatment cycle, defined as the interval of OAC therapy between two consecutive TEE examinations. Results: The study included 216 patients who underwent a total of 294 treatment cycles. At baseline, 47% ( n = 101) of patients were receiving novel oral anticoagulants (NOACs), while 53% ( n = 115) were treated with vitamin-K antagonists (VKAs). Treatment options included switching OAC from VKA to NOAC ( n = 18), from NOAC to a different NOAC ( n = 14) and from NOAC to VKA ( n = 77); or maintaining the same NOAC ( n = 28) or VKA ( n = 157). Overall, LAA thrombi resolved in 70% (152/216) after a mean follow up time of 130 (SD 195) days). No significant differences regarding resolution rate between the five different anticoagulation strategies were observed ( p = 0.866). Multivariate regression analysis identified tricuspid annular plane systolic excursion as independently predictive of LAA thrombus persistence (OR 0.87; 95% CI 0.78–0.98; p = 0.026). Conclusion: This is the largest cohort of patients presenting with LAA thrombi despite adequate OAC. Overall resolution was 70%. Modification of the anticoagulation regimen did not result in higher thrombus resolution rates compared with continuation of the same therapy. Graphical

  • Open Access

    Pulmonary Vein Isolation in Elderly Patients With Atrial Fibrillation and Symptomatic Sick Sinus Syndrome: A Case Series

    by Cerine Benachi, Patrick Nagel, Johannes Lucas, Ulf Landmesser, Gerhard Hindricks, Verena Tscholl, Sebastian Biewener, Martin Huemer, Philipp Attanasio, Tobias Schreiber

    In patients with atrial fibrillation (AF), sinus node disease (SND) represents a potentially reversible concomitant condition. Initial treatment with catheter ablation (CA) aimed at restoration of sinus rhythm may provide an alternative to pacemaker implantation. In this case series, 15 elderly patients (>65 years) with AF and SND underwent CA, with follow‐up monitoring provided by implantable loop recorders (ILR). Despite CA of AF, pacemaker implantation was necessary in 40% of patients during a mean follow‐up period of 37 months.

  • Open Access

    Comparison of Cerebral Micro‐Embolization Detected by Transcranial Doppler Examination Between Radiofrequency Ablation and Pulsed Field Ablation for Atrial Fibrillation

    by Tobias Schreiber, Regina von Rennenberg, Tim Bastian Brämswig, Ulf Landmesser, Gerhard Hindricks, Patrick Nagel, Verena Tscholl, Martin Huemer, Johannes Lucas, Philipp Attanasio, et al.

    Background and Aims: Pulsed Field Ablation (PFA) can establish pulmonary vein isolation via irreversible electroporation and is believed to reduce overall complications; however, periprocedural stroke has also been reported after PFA procedures. Assessment of microembolic signals (MES) measured by transcranial doppler (TCD) allows to monitor cerebral embolization during the procedure and to identify higher risk procedural steps. This study was designed to compare the incidence of MES during different procedural steps between two different PFA systems and radiofrequency ablation (RFA). Methods and Results: Pulmonary vein isolation was performed either using either high‐power short‐duration radiofrequency ablation (HPSD RFA), or PFA using a variable loop circular catheter (VLCC) or a circular multielectrode array catheter (CMAC). MES were compared during transseptal puncture, ablation, left atrial mapping, and introduction/retraction of catheters. Neurological examination was performed pre and post ablation for all patients including the National Institutes of Health Stroke Scale (NIHSS). Fifty‐six consecutive patients (19 female (34%), average age 70 years) were included: 28 in the HPSD RFA group and 14 patients each in the VLCC and CMAC groups. Total MES count was higher for both PFA systems compared to HPSD RFA (VLCC 1402 (IQR 973), CMAC 449 (IQR 193) vs. HPSD RFA 131 (IQR 250); p < 0.001). MES count was higher in VLCC than in CMAC ( p < 0.001). In all groups, MES were most frequently detected during ablation (87% of overall MES). Postprocedural NIHSS did not differ between groups (median NIHSS 0 [IQR 0] in all groups), yet two patients experienced new focal neurological deficits after PFA. Conclusion: Pulsed field ablation was associated with a higher cerebral MES count than high‐power short‐duration radiofrequency ablation, with marked differences between catheter systems. Transcranial doppler indicates ablation as the most embolic step in both PFA and high‐power short duration ablation.


  • P-wave detection performance of the BioMonitor III, Confirm Rx and Reveal Linq implantable loop recorders

    by Tobias Schreiber, Anja Cretnik, Patrick Schauerte, Philipp Lacour, Florian Blaschke, Sebastian Biewener, Saba Suhail, Verena Tscholl, Patrick Nagel, Ulf Landmesser, et al.


  • Open Access

    Safe procedures despite ultra low radiation doses during catheter ablations of atrial and ventricular arrhythmias—A multicenter experience

    by Philipp Attanasio, Martin Huemer, Nora Kaehler, Theresa Keller, Tobias Schreiber, Reinhard Niehues, Dimitra Katsani‐Potempa, Rolf Michael Klein, Ulf Landmesser, Isabel Deisenhofer, et al.

    Introduction: Despite the development of non‐fluoroscopic catheter visualization options, fluoroscopy is still used in most ablation procedures. The aim of this multicenter study was to evaluate the safety and efficacy of a new ultra‐low dose radiation protocol for EP procedures in a large number of patients.Methods and results: A total of 3462 consecutive patients (male 1926 (55.6%), age 64.4 ± 14.0 years, BMI 26.65 ± 4.70) undergoing radiofrequency ablation (left atrial (n = 2316 [66.9%], right atrial (n = 675 [19.5%], or ventricular (n = 471 [13.6%]) in three German centers were included in the analysis. Procedures were performed using a new ultra‐low dose protocol operating at 8nGy for fluoroscopy and 36nGy for cine‐loops. Additionally a very low framerate (2‐3FPS) was used. Using the new protocol very low Air kerma‐area product (KAP) values were achieved for left atrial ablations (104.25 ± 84.22 μGym2), right atrial ablations (70.98 ± 94.79 μGym2) and ablations for ventricular tachycardias or PVCs (78.62 ± 66.59 μGym2). Acute procedural success was achieved in 3289/3388 (97.1%) while the rate of major complications was very low compared to previously published studies not using low dose settings (n = 20, 0.6%).Conclusion: The ultra‐low dose, low framerate protocol leads to very low radiation doses for all EP procedures while neither procedural time, fluoroscopy time nor success or complication rates were compromised. When compared to current real‐world Air KAP data the new ultra‐low dose fluoroscopy protocol reduces radiation exposure by more than 90%.